Exagen Inc Stock Performance
| XGN Stock | USD 4.05 0.05 1.22% |
On a scale of 0 to 100, Exagen holds a performance score of 8. The firm shows a Beta (market volatility) of 1.1, which means a somewhat significant risk relative to the market. Exagen returns are very sensitive to returns on the market. As the market goes up or down, Exagen is expected to follow. Please check Exagen's value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Exagen's price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Exagen Inc are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Exagen displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.49) | Five Day Return 7.65 | Year To Date Return 107.11 | Ten Year Return (78.04) | All Time Return (78.04) |
1 | Acquisition by Black Jeffrey G. of 225000 shares of Exagen subject to Rule 16b-3 | 08/30/2024 |
2 | Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference | 09/04/2024 |
3 | Disposition of 30000 shares by Hunt Holdings Limited Partnership of Exagen at 16.133 subject to Rule 16b-3 | 09/06/2024 |
4 | Shareholders in Exagen have lost 84, as stock drops 12 percent this past week | 09/13/2024 |
5 | Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence | 10/21/2024 |
6 | Acquisition by Birk Brian of 9000 shares of Exagen subject to Rule 16b-3 | 10/25/2024 |
7 | Exagen Inc. Reports Third Quarter 2024 Results | 11/12/2024 |
8 | Exagen Inc Q3 2024 Earnings Call Highlights Navigating Challenges with Strategic Growth ... | 11/13/2024 |
9 | Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform | 11/14/2024 |
10 | Exagen Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag | 11/15/2024 |
11 | Exagen CEO, President Director Acquires 7.7 percent More Stock | 11/21/2024 |
| Begin Period Cash Flow | 62.6 M |
Exagen |
Exagen Relative Risk vs. Return Landscape
If you would invest 300.00 in Exagen Inc on August 27, 2024 and sell it today you would earn a total of 105.00 from holding Exagen Inc or generate 35.0% return on investment over 90 days. Exagen Inc is generating 0.6% of daily returns assuming volatility of 5.2669% on return distribution over 90 days investment horizon. In other words, 46% of stocks are less volatile than Exagen, and above 89% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Exagen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exagen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Exagen Inc, and traders can use it to determine the average amount a Exagen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1139
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.27 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Exagen is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Exagen by adding it to a well-diversified portfolio.
Exagen Fundamentals Growth
Exagen Stock prices reflect investors' perceptions of the future prospects and financial health of Exagen, and Exagen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exagen Stock performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 73.83 M | ||||
| Shares Outstanding | 17.64 M | ||||
| Price To Book | 5.62 X | ||||
| Price To Sales | 1.28 X | ||||
| Revenue | 52.55 M | ||||
| Gross Profit | 21.35 M | ||||
| EBITDA | (19.15 M) | ||||
| Net Income | (23.69 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 23.72 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (14.46 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Market Capitalization | 72.31 M | ||||
| Total Asset | 56.94 M | ||||
| Retained Earnings | (279.22 M) | ||||
| Working Capital | 35.94 M | ||||
About Exagen Performance
By examining Exagen's fundamental ratios, stakeholders can obtain critical insights into Exagen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exagen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 45.38 | 47.65 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (1.04) | (1.10) |
Things to note about Exagen Inc performance evaluation
Checking the ongoing alerts about Exagen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exagen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exagen Inc is way too risky over 90 days horizon | |
| Exagen Inc appears to be risky and price may revert if volatility continues | |
| Exagen Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 52.55 M. Reported Net Loss for the year was (23.69 M) with profit before taxes, overhead, and interest of 21.35 M. | |
| Exagen Inc has about 76.39 M in cash with (14.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Exagen Inc has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: Exagen CEO, President Director Acquires 7.7 percent More Stock |
- Analyzing Exagen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exagen's stock is overvalued or undervalued compared to its peers.
- Examining Exagen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exagen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exagen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exagen's stock. These opinions can provide insight into Exagen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.